Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biological Predictive Factors of Response to Epoetin Zeta in Low Risk MDS
NCT03598582Phase 4Completed
- Start
- Jan 2013
- Primary completion
- May 2017
- Modality
- Cytokines & Interferons
01
Overview
A Phase 4 trial of epoetin alfa or beta in myelodysplastic syndrome (MDS). Started Jan 2013; status: completed.
02
Drugs
epoetin alfa or beta
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03598582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03598582.